Haldol Depot (Haloperidol Decanoate)

Haldol Depot is indicated for several psychiatric indications where long‑acting antipsychotic therapy is appropriate.

• Management of schizophrenia in adults and adolescents.
• Treatment of acute psychotic episodes when oral therapy is not feasible.
• Maintenance therapy for chronic psychotic disorders to reduce relapse risk.
• Adjunctive use in patients with schizoaffective disorder requiring depot medication.
• Stabilization of patients with bipolar disorder experiencing severe manic episodes where typical antipsychotics are indicated.
• Long‑term control of psychosis in patients with poor medication adherence.

Side effects of Haldol Depot reflect its dopamine antagonism and can vary in frequency and severity.

Common

• Sedation or drowsiness, especially after the initial injection.
• Extrapyramidal symptoms such as tremor, muscle rigidity, akathisia, or parkinsonian‑like signs.
• Dry mouth, increased salivation, or other anticholinergic‑type effects.
• Weight gain, increased appetite, or metabolic changes.
• Mild orthostatic dizziness or light‑headedness.

Serious

• Neuroleptic malignant syndrome, presenting with fever, muscle rigidity, autonomic instability, and altered mental status.
• Tardive dyskinesia, involving persistent involuntary movements of the face, tongue, or limbs.
• Severe hypotension, cardiac arrhythmias, or prolonged QT interval leading to cardiac events.
• Elevated prolactin levels causing galactorrhea, menstrual disturbances, or sexual dysfunction.

Before initiating Haldol Depot, clinicians should evaluate several safety considerations and patient‑specific factors.

• Assess history of cardiovascular disease, as the drug may affect blood pressure and cardiac rhythm.
• Monitor for signs of extrapyramidal symptoms and tardive dyskinesia, especially with long‑term use.
• Evaluate liver and renal function; dose adjustments may be required in severe impairment.
• Use caution in patients with a history of seizures, neuroleptic malignant syndrome, or severe dehydration.
• Consider pregnancy and lactation status; the medication’s safety profile in these conditions is not well established.
• Review any history of hypersensitivity to haloperidol or other butyrophenone agents.

Haldol Depot can interact with other medicines, influencing its efficacy or increasing the risk of adverse effects.

Avoid

• Other dopamine‑blocking agents or high‑potency antipsychotics, which may amplify extrapyramidal toxicity.
• Medications that prolong the QT interval, such as certain antiarrhythmics, macrolide antibiotics, or antifungals.
• Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin) that can raise haloperidol levels.

Use with caution

• CYP3A4 inducers like carbamazepine or rifampin, which may reduce drug exposure.
• CNS depressants, including benzodiazepines or opioids, which can increase sedation.
• Anticholinergic agents that may mask extrapyramidal symptoms.
• Antihypertensive drugs, as additive hypotensive effects may occur.